=Miragen Therapeutics (MGEN)

Miragen Therapeutics (MGEN) announced that new preclinical safety and feasibility data on inhaled delivery of MRG-201, a microRNA-29 mimic, for the treatment of pulmonary fibrosis will be presented at the European Respiratory Society International Congress on September 12, 2017.


Miragen Therapeutics, Inc., a clinical stage biopharmaceutical company, develops microRNA-targeted therapies for various unmet medical needs. The company's lead product candidates, which are in Phase 1 clinical trial include MRG-106, an inhibitor of microRNA (miR)-155 for the treatment of certain cancers; and MRG-201, a replacement for miR-29 for the treatment of pathological fibrosis. Its pre-clinical products include MRG-107, an inhibitor of miR-155 for the treatment of amyotrophic lateral sclerosis; and MRG-110 that targets miR-92c for the treatment of revascularization disease. The company has strategic collaboration with Les Laboratoires Servier and the Institut de Recherches Servier to develop product candidates for the treatment of cardiovascular diseases. It also has license agreements with the Board of Regents of The University of Texas System, Roche Innovation Center Copenhagen A/S, and t2cure GmbH; patent license agreement with The Brigham and Women's Hospital; and subcontract agreement with Yale University. The company was founded in 2006 and is based in Boulder, Colorado.